Zarling E J
Department of Medicine, Loyola University Medical Center, Maywood, Illinois 60153, USA.
Clin Ther. 1999 Dec;21(12):2038-46; discussion 2037. doi: 10.1016/s0149-2918(00)87235-5.
Gastroesophageal reflux is a common condition caused mainly by motility disorders of the upper gastrointestinal tract. The most effective therapy combines acid suppression with a promotility agent. Nizatidine is a well-tolerated and effective histamine-2 (H2)-receptor antagonist used to suppress gastric acid secretion. Animal and human studies have conclusively demonstrated that nizatidine also has prokinetic activity comparable to that of cisapride, and its effect is evident <1 hour after administration of doses commonly used in clinical practice. This prokinetic activity occurs through noncompetitive inhibition of acetylcholine; this inhibition approximates the inhibition caused by neostigmine. Nizatidine appears to possess a prokinetic mechanism that may be helpful in treating patients with gastroesophageal reflux.
胃食管反流是一种常见病症，主要由上消化道动力障碍引起。最有效的治疗方法是将抑酸剂与促动力剂联合使用。尼扎替丁是一种耐受性良好且有效的组胺-2（H2）受体拮抗剂，用于抑制胃酸分泌。动物和人体研究已确凿表明，尼扎替丁还具有与西沙必利相当的促动力活性，且在临床实践中常用剂量给药后不到1小时其效果就很明显。这种促动力活性是通过对乙酰胆碱的非竞争性抑制产生的；这种抑制作用与新斯的明引起的抑制作用相近。尼扎替丁似乎具有一种促动力机制，这可能有助于治疗胃食管反流患者。
